SEC Form 4/A · accession 0001209191-15-057243

ANTARES PHARMA, INC. · ATRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — President & CEO · Director

Period of report

May 28, 2015

Accepted (ET)

Jun 29, 2015 · 6:47 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001016169

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	May 28, 2018	A	245,532	$0.00	A	445,254	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F3,F4,F5	$2.18	May 28, 2015	A	293,670	A	—	May 27, 2025	Common Stock	293,670	293,670	D

F1Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
F2The shares reported here represent the total number of securities beneficially owned following the reported transaction, excluding awards of performance stock units previously reported as 182,724 shares of common stock that remain subject to the achievement of a performance goal pursuant to the terms of the award and thus were removed from the total amount of securities beneficially owned.
F3Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
F4The number of options granted has been reduced from 498,310 to 293,670 based on a determination by the Compensation Committee on June 25, 2015.
F5The options vest in equal quarterly installments over three years from the date of grant.